British Medical Journal (BMJ)

BMJ is a partially open-access peer-reviewed medical journal. Originally called the British Medical Journal, the title was officially shortened to BMJ in 1988. The journal is published by the BMJ Group, a wholly owned subsidiary of the British Medical Association. The editor in chief of BMJ is Fiona Godlee, who was appointed in February 2005. The journal began publishing on 3 October 1840 as the Provincial Medical and Surgical Journal and quickly attracted the attention of physicians around the world through its publication of high-impact original research articles and unique case reports. The BMJ s first editors were P. Hennis Green, lecturer on the diseases of children at the Hunterian School of Medicine, who also was its founder and Robert Streeten of Worcester, a member of the PMSA council. The first issue of the British Medical Journal was 16 pages long and contained three simple woodcut illustrations. The longest items were the editors introductory editorial and a report of the Provincial Medical and Surgical Association s Eastern Branch. Other pages included a condensed version of Henry Warburton s medical reform bill, book reviews, clinical papers, and case notes.

Publisher
BMJ Group
Country
United Kingdom
History
1840–present
Impact factor
13.471 (2011)

Some content from Wikipedia, licensed under CC BY-SA

Cardiology

Sometimes, a non-invasive procedure will suffice

When a patient complains about chest pain, diagnosis will usually involve catheter angiography to evaluate the adequacy of blood supply to the heart. Researchers from Charité - Universitätsmedizin Berlin have now established ...

Cardiology

Should STEMI patients recover in the ICU?

A trip to an intensive care unit can be more than twice as costly as a stay in a non-ICU hospital room, but a new study finds intensive care is still the right option for some vulnerable patients after a severe heart attack.

Diseases, Conditions, Syndromes

Heartburn drugs again tied to fatal risks

(HealthDay)—People who use common heartburn drugs for months to years may face heightened risks of dying from heart disease, kidney failure or stomach cancer, a new study suggests.

page 1 from 49